Potential Regulatory & Policy Implications

How can companies position themselves to attract venture capital and federal funding and maximize its impact?

It all comes down to the efficacy of the therapy of the company. That's the bottom line. If you have a promising therapy, I think you know coming into 2025 liquidity is coming back, and I think a number of venture companies, venture funds, will have a better ear for, you know, those promising therapies than was two years ago. Any company with a promising therapy can actually reach out to NIH, National Institute of Health, is effectively backed by the taxpayer, trying to move forward, you know, health initiatives across the country. So, I would advise any company that that thinks they have a promising therapy to reach out to them. They're receptive. That’s their job.

What are the potential regulatory and policy implications of these trends, and how can companies proactively address these challenges to ensure continued growth and success?

Over the past year, there's been a lot of talk in Congress, and actually, it's moved into action of repatriating the manufacturing and the research on the development of these therapies back into the United States. If you look at the bio secure act with which passed in the House, I believe, about a week ago, that act was written to address security concerns between the United States and pharma. You know, pharmaceutical and biotech industry vis a vis China, they specifically mentioned a company called WuXi AppTec and all their affiliates, the Biosecure Act. Also, you know, mentions that, you know, the data that is being procured by. Or produced by these companies in China, doing trials and third party research on behalf of American companies is not secure, is being shared with the Chinese government and so on and so forth.

So, this act basically mandates that, over a period of time, that American companies have to bring back this research and development back to the nationally, domestically, I should say that's going to have a profound impact on companies taking space for domestic contract research organizations, CDMOs, CROs and CMOs are going to have to have to fill the shoes of those Chinese companies, you know, and bring that domestically, back here. So, I do think it's going to have wide ranging impacts on those companies, first of all, growing in this country, right? Because the American companies are going to have to effectively extricate themselves from these Chinese companies and bring it here. And those companies are going to have to hire a lot of people.

So, we're going to have to address that a lot of colleges are going to have to prepare for programs for people to understand how to actually do this science and work on this manufacturing. And you're going to have a lot of companies taking space and locations where there is existing space and existing talent pool, I think will do extremely well. You know, areas like Northern Jersey, New York area, Philadelphia, North Carolina, where they have existing manufacturing facilities in place and a history of that, I think will do extremely well in response to this, this Biosecure Act.